Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Loading...

Monday, February 13, 2023

Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants

AlexandrosSfakianakis shared this article with you from Inoreader

Abstract

Bebtelovimab (LY-CoV1404) is a monoclonal antibody showing remarkable neutralizing capacity against all SARS-CoV-2 variants of concern (VOCs) as of June 2022, including the Omicron variant and its subvariants

This article is protected by copyright. All rights reserved.
View on Web
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)